{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T12:14:21Z","timestamp":1761826461763,"version":"build-2065373602"},"reference-count":22,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,2,6]],"date-time":"2024-02-06T00:00:00Z","timestamp":1707177600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Radiology Case Reports"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1016\/j.radcr.2024.02.018","type":"journal-article","created":{"date-parts":[[2024,2,29]],"date-time":"2024-02-29T14:57:05Z","timestamp":1709218625000},"page":"2013-2019","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Intestinal Perforation in a patient with peritoneal carcinomatosis from colon cancer treated with Regorafenib. Description of a case and review of the literature"],"prefix":"10.1016","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5678-4161","authenticated-orcid":false,"given":"Maria Alessandra","family":"Bellia","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carmelo","family":"Sofia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Adele","family":"Marino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carmelo","family":"Mazzeo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4720-3345","authenticated-orcid":false,"given":"Santino Antonio","family":"Biondo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eugenio","family":"Cucinotta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1092-8975","authenticated-orcid":false,"given":"Francesco","family":"Fleres","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.radcr.2024.02.018_bib0001","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1002\/ijc.25864","article-title":"Regorafenib (BAY 73-4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity","volume":"129","author":"Wilhelm","year":"2011","journal-title":"Int J Cancer"},{"issue":"2","key":"10.1016\/j.radcr.2024.02.018_bib0002","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1007\/s11523-014-0333-x","article-title":"Regorafenib as a single-agent in the treatment of patients with gastrointestinal tumors: an overview for pharmacists","volume":"10","author":"Rey","year":"2015","journal-title":"Target Oncol"},{"issue":"5","key":"10.1016\/j.radcr.2024.02.018_bib0003","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1080\/1120009X.2016.1183290","article-title":"Gastrointestinal perforation during regorafenib administration in a case with hepatic metastases of colon cancer","volume":"29","author":"Ogata","year":"2017","journal-title":"J Chemother"},{"key":"10.1016\/j.radcr.2024.02.018_bib0004","first-page":"207","article-title":"Yoshiteru watanabe and kaori koyama intestinal perforation in a patient with colon cancer during treatment with regorafenib: a case report and review of the literature tohoku","volume":"254","author":"Ouchi","year":"2021","journal-title":"J.Exp. Med.,"},{"key":"10.1016\/j.radcr.2024.02.018_bib0005","unstructured":"Stivarga\u00ae (regorafenib) label- accessdata FDA https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/203085s007lbl.pdf."},{"issue":"9863","key":"10.1016\/j.radcr.2024.02.018_bib0006","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/S0140-6736(12)61857-1","article-title":"GRID study investigators. Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial","volume":"381","author":"Demetri","year":"2013","journal-title":"Lancet"},{"issue":"9863","key":"10.1016\/j.radcr.2024.02.018_bib0007","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/S0140-6736(12)61900-X","article-title":"Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial","volume":"381","author":"Grothey","year":"2013","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.radcr.2024.02.018_bib0008","doi-asserted-by":"crossref","first-page":"245","DOI":"10.5152\/tjg.2018.17316","article-title":"Intestinal perforation after regorafenib usage","volume":"29","author":"Sar\u0131c\u0131","year":"2018","journal-title":"Turk J Gastroenterol"},{"issue":"1","key":"10.1016\/j.radcr.2024.02.018_bib0009","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1186\/s12885-019-5753-7","article-title":"First-line single-agent regorafenib in frail patients with metastatic colorectal cancer: a pilot phase II study of the Spanish Cooperative Group for the Treatment of Digestive Tumors (TTD)","volume":"19","author":"Carrato","year":"2019","journal-title":"BMC Cancer"},{"key":"10.1016\/j.radcr.2024.02.018_bib0010","unstructured":"Avastin\u00ae (bevacizumab) label- accessdata FDA https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2011\/125085s225lbl.pdf."},{"issue":"10","key":"10.1016\/j.radcr.2024.02.018_bib0011","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1016\/S1470-2045(14)70330-4","article-title":"FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial","volume":"15","author":"Heinemann","year":"2014","journal-title":"Lancet Oncol"},{"issue":"8","key":"10.1016\/j.radcr.2024.02.018_bib0012","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1093\/annonc\/mdw235","article-title":"Aderka D,et al. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer","volume":"27","author":"Van Cutsem","year":"2016","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.radcr.2024.02.018_bib0013","doi-asserted-by":"crossref","DOI":"10.1136\/esmoopen-2016-000135","article-title":"S-1 and oxaliplatin (SOX) plus bevacizumab versus mFOLFOX6 plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer: updated overall survival analyses of the open-label, non-inferiority, randomised phase III: SOFT study","volume":"2","author":"Baba","year":"2017","journal-title":"ESMO Open"},{"issue":"1","key":"10.1016\/j.radcr.2024.02.018_bib0014","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s10147-019-01485-z","article-title":"Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2019 for the treatment of colorectal cancer","volume":"25","author":"Watanabe","year":"2020","journal-title":"Int J Clin Oncol"},{"key":"10.1016\/j.radcr.2024.02.018_bib0015","article-title":"Readministration of Cancer Drugs in a Patient with Chemorefractory Metastatic Colorectal Cancer","volume":"2020","author":"Kawagoe","year":"2020","journal-title":"Case Rep Oncol Med"},{"issue":"8","key":"10.1016\/j.radcr.2024.02.018_bib0016","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.3109\/0284186X.2013.835070","article-title":"Regorafenib use as a possible cause of intestinal perforation","volume":"52","author":"Adenis","year":"2013","journal-title":"Acta Oncol"},{"key":"10.1016\/j.radcr.2024.02.018_bib0017","doi-asserted-by":"crossref","unstructured":"Doi A, Shitara K, Fukuoka S et al Gastrointestinal pertoration and fistula formation in 5 patients with colorectal cancer during treatment with regorafenib clinical colorectal cancer 2015, 26 100 DOI: https:\/\/doi.org\/10.1016\/j.clcc.2016.11.003.","DOI":"10.1093\/annonc\/mdv471.88"},{"issue":"6","key":"10.1016\/j.radcr.2024.02.018_bib0018","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/S1470-2045(09)70112-3","article-title":"Risk of gastrointestinal perforation in patients with cancer treated with bevacizumab: a meta-analysis","volume":"10","author":"Hapani","year":"2009","journal-title":"Lancet Oncol"},{"issue":"3","key":"10.1016\/j.radcr.2024.02.018_bib0019","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.ygyno.2010.11.009","article-title":"Clinical predictors of bevacizumab-associated gastrointestinal perforation","volume":"120","author":"Tanyi","year":"2011","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.radcr.2024.02.018_bib0020","series-title":"Imaging of complications and toxicity following tumor therapy. Medical radiology","article-title":"Imaging of gastrointestinal complications and toxicity following tumor therapy","author":"Viswanathan","year":"2014"},{"key":"10.1016\/j.radcr.2024.02.018_bib0021","first-page":"437","article-title":"Bevacizumab-induced bowel perforation","volume":"111","author":"Sliesoraitis","year":"2011","journal-title":"J Am Osteopath Assoc"},{"key":"10.1016\/j.radcr.2024.02.018_bib0022","doi-asserted-by":"crossref","first-page":"5365","DOI":"10.2147\/CMAR.S255332","article-title":"Regorafenib for metastatic colorectal cancer: an analysis of a registry-based cohort of 555 patients","volume":"12","author":"Novakova-Jiresova","year":"2020","journal-title":"Cancer Manag Res"}],"container-title":["Radiology Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1930043324001092?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1930043324001092?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T12:08:56Z","timestamp":1761826136000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1930043324001092"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5]]},"references-count":22,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,5]]}},"alternative-id":["S1930043324001092"],"URL":"https:\/\/doi.org\/10.1016\/j.radcr.2024.02.018","relation":{},"ISSN":["1930-0433"],"issn-type":[{"type":"print","value":"1930-0433"}],"subject":[],"published":{"date-parts":[[2024,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Intestinal Perforation in a patient with peritoneal carcinomatosis from colon cancer treated with Regorafenib. Description of a case and review of the literature","name":"articletitle","label":"Article Title"},{"value":"Radiology Case Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.radcr.2024.02.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Inc. on behalf of University of Washington.","name":"copyright","label":"Copyright"}]}}